Oncology Division

Nancy L. Bartlett, MD

Department of Medicine
Oncology Division
Medical Oncology

Research Interests

  • Non-Hodgkin's lymphoma
  • Hodgkin's disease
  • Chronic lymphocytic leukemia


  • 314-362-5654 (tel)
  • 314-747-5123 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8056
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110


My primary research interest is developing and conducting clinical trials for patients with lymphoma. I serve as vice-chair of the Alliance (cooperative group funded by the NCI) Lymphoma Core Committee and help plan trials for Hodgkin lymphoma (HL). I worked closely with the pharmaceutical company Seattle Genetics over the last 5 years testing anti-CD30 based targeted therapy for HL, initially the monoclonal antibody SGN-30 (Bartlett et al. Blood 2008), and more recently the antibody drug conjugate brentuximab vedotin (Younes et al. NEJM 2010). I am actively involved in efforts to combine brentuximab vedotin with chemotherapy as first line therapy in HL. In collaboration with Washington University faculty member Todd Fehniger, we evaluated the use of lenalidomide in recurrent HL (Fehniger et al. Blood 2011) and are currently participating in a study with investigators at Ohio State combining lenalidomide with panobinostat for recurrent HL. I serve as principal investigator for a phase II study of ibrutinib, a btk inhibitor, in relapsed follicular lymphoma. We have a strong portfolio of cooperative group and industry sponsored trials available for HL and most subtypes of non-Hodgkin lymphoma (NHL) including: newly diagnosed and relapsed mantle cell lymphoma (high dose therapy and stem cell transplant as first line therapy and a Phase II trial of ibrutinib for relapsed disease), diffuse large cell lymphoma (Phase III study of DA-EPOCH-R vs. R-CHOP for untreated large cell and several trials for relapsed large cell including fostamatinib, AEB071, inotuzumab, and MEDI-551 + DHAP), newly diagnosed PTCL (CEOP + Praletrexate), newly diagnosed follicular lymphoma (Rituxan-bendamustine vs. Rituxan-lenalidomide) and relapsed follicular lymphoma (ibrutinib). In addition to my interest in clinical trial development, I have worked closely with other Washington University investigators on exome sequencing of follicular and transformed large cell lymphoma. Our goals are to expand these genome studies to larger sets of follicular and transformed lymphoma patients and to study other subtypes of lymphoma.